Related Experiment Videos
Length distribution of CDRH3 in antibodies
1Department of Biochemistry, Northwestern University, Evanston, Illinois 60208.
Insights
Antibody heavy chain CDRH3 sequences show significant length variation, especially in humans. This diversity, along with amino acid changes, generates numerous antibody specificities and affects antibody binding site shape.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Antibody diversity is crucial for immune response.
- Complementarity determining regions (CDRs) dictate antigen binding.
- The third heavy chain CDR (CDRH3) is known for its variability.
Purpose of the Study:
- To analyze the length variation of CDRH3 sequences across species.
- To understand the contribution of CDRH3 to antibody diversity and binding site shape.
Main Methods:
- Bioinformatic analysis of antibody heavy chain sequences.
- Comparative analysis of CDRH3 lengths in human and other species.
Main Results:
- Human CDRH3 sequences exhibit significant length variation (2-26 amino acids).
- Length variation in CDRH3 is less pronounced in other species.
- CDRH3 length and sequence variations contribute to a vast antibody repertoire.
- These variations influence the structural conformation of the antibody combining site.
Conclusions:
- CDRH3 length polymorphism is a key driver of antibody diversity.
- The structural plasticity of CDRH3 is essential for generating broad antibody specificities.
- Understanding CDRH3 variation is vital for antibody engineering and therapeutic development.
Abstract:
Sequences of the third complementarity determining region of antibody heavy chains (CDRH3s) are listed according to their length. Human sequences vary from 2 to 26 amino acids residues, but less extensively in other species. When combined with the other five complementarity determining regions, this enormous length variation of CDRH3, together with amino acid substitutions in their sequences, can provide a very large number of antibody specificities and can influence the shape of antibody combining sites.